Table 6.
The comparison of the results from intra-laboratory pre-validated assay to the results from other in vitro methods, clinical studies and animal models.
| Reference chemical | Results from intra-laboratory pre-validated angiogenesis test method | Results using other in vitro angiogenesis test methods | Results from clinical trials | Results using animal models | ||
|---|---|---|---|---|---|---|
| Mild inhibition (% of control) <20% | Moderate inhibition (% of control) 40–60% | Strong inhibition (% of control) 75–85% | Inhibitory effect and concentration | Cmax | Effective dose (ED) | |
| Acetyl salicylic acid | 1.8–8 μg/ml (10–100 μM) | 180 μg/ml (1000 μM) | 270 μg/ml (1500 μM) | Moderate 500 μM (Borthwick et al., 2006) | • 260–1026 μM (Juárez Olguín et al., 2004) | • 26–300 μM, CAM model (Sharma et al., 2001) |
| • 0–25 μg/ml (Maalouf et al., 2009) | ||||||
| • 170 ± 96.7 ng/ml (Bae et al., 2008) | ||||||
| Erlotinib (EGF receptor tyrosine kinase inhibitor) | 0.04–40 ng/ml (0.5 nM–0.1 μM) | 4 μg/ml (10 μM) | 22 μg/ml (50 μM) | Mild 1–20 μM (Birle and Hedley, 2006), Moderate 10 μM (Jimeno et al., 2007) | • 0.3–1.13 μg/ml (Herbst et al., 2005) | • 50 mg/kg, Mouse carcinoma model (Jimeno et al., 2007) |
| • 0.251–10.7 μg/ml (Ranson et al., 2010a) | • 50 mg/kg, Mouse tumor model (Cerniglia et al., 2009) | |||||
| • 2.93 ± 1.3 μg/ml (Ranson et al., 2010b) | ||||||
| • 0.3 μM (Clarke et al., 2010) | ||||||
| • 0.56–4 μM (Kraut et al., 2010) | ||||||
| Levamisole | 2–240 ng/ml (0.01–1 μM) | 25–120 μg/ml (100–500 μM) | 240–500 μg/ml (1000–2000 μM) | Mild 500 μM, moderate 750–1000 μM, strong 2000 μM (Friis et al., 2005), strong 2000 μM (Sylvest et al., 2010) | • 0.62 μg/ml–1.27 μg/ml (Reid et al., 1998) | • 1.2–12 mg/kg, Nude mouse tumor model (Friis et al., 2005) |
| • 0.716 ± 0.217 μg/ml (Kouassi et al., 1986) | • Cmax 0.37 μg/ml calf parasite infection (Taylor et al., 1988 | |||||
| 2-Methoxyestradiol | 3–60 ng/ml (0.01–0.2 μM) | 300 ng/ml (1 μM) | 600 ng/ml (2 μM) | Mild 10 μM, moderate 50 μM (Kang et al., 2006), Mild 0.5 μM, moderate 1 μM (Dobos et al., 2004) | • 3.3 ng/ml (Tevaarwerk et al., 2009) | • 100 mg/kg Murine rheumatoid arthritis model (Plum et al., 2009) |
| • 30.27 ± 20.18 ng/ml (Matei et al., 2009) | • 7.5 mg/kg, 75 mg/kg Mouse tumor model (Dobos et al., 2004) | |||||
| • 3.0–21.4 ng/ml (Dahut et al., 2006) | ||||||
| • 1.4–13.2 ng/ml (James et al., 2007) | ||||||
| • 2.2–9.6 ng/ml (Sweeney et al., 2005) | ||||||
| Thalidomide | 2–25 μg/ml (10–100 μM) | 77–100 μg/ml (300–400 μM) | - | - | • 2 μg/ml (Kakimoto et al., 2002) | • 100 mg/kg, Rat Alzheimer model (Ryu and McLarnon, 2008) |
| • 1.68 ± 0.41 μg/ml (Murakami et al., 2009) | • 19–1000 μM, CAM model (Sharma et al., 2001) | |||||
| • 1.44 ± 0.50 μg/ml (Kamikawa et al., 2006) | ||||||
| • 0.43–1.03 μg/ml (Vieira and Valente Mdo, 2009) | ||||||
| Anti-VEGF | 0.01–0.1 μg/ml | 0.5–1 μg/ml | 25–50 μg/ml | Strong 0.1 mg/ml-10 mg/ml (Sims et al., 2008), Strong 5 μg/ml (Friis et al., 2006), Strong 10 μg/ml (Friis et al., 2003) | • 363 μg/ml (Herbst et al., 2005) | • 2–4 mg/kg, Mouse carcinoma model (Sims et al., 2008) |
| • 123.2 ± 16.4 μg/ml (Wu et al., 2010) | • Cmax 104.46 ± 1.44 ng/ml, injection in rabbit (Kim et al., 2010) | |||||
| • 11.94–194.08 μg/ml (Ning et al., 2010) | • Cmax 1430 ± 186 ng/ml, vitreous injection macaque eyes (Miyake et al., 2010) | |||||
| • 20.7–24.2 ng/ml (Sharma et al., 2010) | • Cmax 676 ± 100 μg/ml, cynomolgus monkeys (Xu et al., 2008) | |||||
| • 16.6–42.5 μg/ml (Krohne et al., 2008) | ||||||
| • 2.63–165 μg/ml (Zhu et al., 2008) | ||||||